Antiangiogenic strategies for the treatment of gliomas

Glioblastoma: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies

Volumn , Issue , 2010, Pages 243-263

  Bazzoli, Elena ^a   Omuro, Antonio M P ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Antiangiogenic therapy; Malignant gliomas; Signaling pathways

Indexed keywords

EID: 84872192116     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-0410-2_12     Document Type: Chapter

References (127)

1. Abe T, Okamura K, Ono M et al (1993) Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J Clin Invest 92:54-61
2. Abounader R, Laterra J (2005) Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 7:436-451
3. Alavi A, Hood JD, Frausto R et al (2003) Role of raf in vascular protection from distinct apoptotic stimuli. Science 301:94-96
4. Algire GH, Chalkely HW, Legallais FY et al (1945) Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 6:73-85
5. Asahara T, Murohara T, Sullivan A et al (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967
6. Batchelor TT, Sorensen AG, Di Tomaso E et al (2007) Azd2171, a pan-vegf receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95
7. Bergsland E, Dickler MN (2004) Maximizing the potential of bevacizumab in cancer treatment. Oncologist 9(suppl 1):36-42
8. Bertolini F, Shaked Y, Mancuso P et al (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845
9. Blankenberg FG, Backer M V, Levashova Z et al (2006) In vivo tumor angiogenesis imaging with site-specific labeled (99m) tc-hynic-vegf. Eur J Nucl Med Mol Imaging 33:841-848
10. Board R, Jayson GC (2005) Platelet-derived growth factor receptor (pdgfr): a target for anticancer therapeutics. Drug Resist Updat 8:75-83
11. Brat DJ, Castellano-Sanchez A, Kaur B et al (2002) Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 9:24-36
12. Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7:122-133
13. Bredow S, Lewin M, Hofmann B et al (2000) Imaging of tumour neovasculature by targeting the tgf-beta binding receptor endoglin. Eur J Cancer 36:675-681
14. Brem S (1976) The role of vascular proliferation in the growth of brain tumors. Clin Neurosurg 23:440-453
15. Brem S, Cotran R, Folkman J (1972) Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48:347-356
16. Brem S, Tsanaclis AM, Gately S et al (1992) Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 70:2673-2680
17. Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82
18. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
19. Chang SM, Lamborn KR, Malec M et al (2004) Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60:353-357
20. Chen W, Delaloye S, Silverman DH et al (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18f] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25:4714-4721
21. Cheng SY, Huang HJ, Nagane M et al (1996) Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 93:8502-8507
22. Chi A, Norden AD, Wen PY (2007) Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 7:1537-1560
23. Conrad C, Friedman H, Reardon D et al (2004) A phase I/II trial of single-agent ptk 787/zk 222584 (ptk/zk), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (gbm). J Clin Oncol (meeting abstract)
24. Coomber BL (1995) Suramin inhibits c6 glioma-induced angiogenesis in vitro. J Cell Biochem 58:199-207
25. D'amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085
26. Damiano V, Melisi D, Bianco C et al (2005) Cooperative antitumor effect of multitargeted kinase inhibitor zd6474 and ionizing radiation in glioblastoma. Clin Cancer Res 11:5639-5644
27. De Bouard S, Herlin P, Christensen JG et al (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9:412-423
28. De Vries C, Escobedo JA, Ueno H et al (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991
29. Desjardins A, Vredenburgh JJ, Quinn J et al (2006) Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (vegf), and chemotherapy for recurrent malignant glioma patients: series of cases. Neuro Oncol (meeting abstracts) 8:454
30. Ding H, Wu X, Roncari L et al (2000) Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer 88:584-592
31. Dresemann G (2005) Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16:1702-1708
32. Du R, Lu K V, Petritsch C et al (2008) Hif1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-220
33. Dvorak HF (2005) Angiogenesis: update 2005. J Thromb Haemost 3:1835-1842
34. Fayed N, Morales H, Modrego PJ et al (2006) Contrast/noise ratio on conventional mri and choline/creatine ratio on proton mri spectroscopy accurately discriminate low-grade from highgrade cerebral gliomas. Acad Radiol 13:728-737
35. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581-611
36. Ferrara N (2005) Vegf as a therapeutic target in cancer. Oncology 69(suppl 3):11-16
37. Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-vegf antibody for treating cancer. Nat Rev Drug Discov 3:391-400
38. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
39. Folkman J, Merler E, Abernathy C et al (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275-288
40. Gagliardi AR, Kassack M, Kreimeyer A et al (1998) Antiangiogenic and antiproliferative activity of suramin analogues. Cancer Chemother Pharmacol 41:117-124
41. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
42. Gerstner ER, Duda DG, Di Tomaso E et al (2007) Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Invest Drugs 16:1895-1908
43. Goldbrunner RH, Bendszus M, Wood J et al (2004) Ptk787/zk222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 55:426-432; discussion 32
44. Goldman CK, Kim J, Wong WL et al (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133
45. Gossmann A, Helbich TH, Kuriyama N et al (2002) Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to antiangiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 15:233-240
46. Greenblatt M, Shubi P (1968) Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J Natl Cancer Inst 41:111-124
47. Guha A (1998) Ras activation in astrocytomas and neurofibromas. Can J Neurol Sci 25:267-281
48. Guo W, Giancotti FG (2004) Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5:816-826
49. Hariharan S, Gustafson D, Holden S et al (2007) Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (emd 121974), in patients with advanced solid tumors. Ann Oncol 18:1400-1407
50. Heidenreich R, Machein M, Nicolaus A et al (2004) Inhibition of solid tumor growth by gene transfer of vegf receptor-1 mutants. Int J Cancer 111:348-357
51. Heymach JV (2005) Zd6474-clinical experience to date. Br J Cancer 92(suppl 1):S14-S20
52. Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and vegf. Science 284:1994-1998
53. Holash J, Davis S, Papadopoulos N et al (2002) Vegf-trap: a vegf blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393-11398
54. Hormigo A, Gutin PH, Rafii S (2007) Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers. Cancer Cell 11:6-8
55. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
56. Ide AG, Baker NH, Warren SL (1939) Vascularization of the brown pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 42:891-899
57. Im SA, Gomez-Manzano C, Fueyo J et al (1999) Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59:895-900
58. Jain RK, Safabakhsh N, Sckell A et al (1998) Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci USA 95:10820-10825
59. Jouanneau E (2008) Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery 62:31-50; discussion 2
60. Jun. HT, Sun J, Rex K et al (2007) Amg 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in u-87mg cells and xenografts. Clin Cancer Res 13:6735-6742
61. Karcher S, Steiner HH, Ahmadi R et al (2006) Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 118:2182-2189
62. Kaur B, Brat DJ, Devi NS et al (2005) Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 24:3632-3642
63. Keck PJ, Hauser SD, Krivi G et al (1989) Vascular permeability factor, an endothelial cell mitogen related to pdgf. Science 246:1309-1312
64. Kesari S, Schiff D, Doherty L et al (2007) Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol 9:354-363
65. Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844
66. Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033-8040
67. Konner J, Dupont J (2004) Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (vegf trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 4(suppl 2):S81-S85
68. Leon SP, Folkerth RD, Black PM (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362-372
69. Leung DW, Cachianes G, Kuang WJ et al (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309
70. Levin VA, Phuphanich S, Yung WK et al (2006) Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 78:295-302
71. Li VW, Folkerth RD, Watanabe H et al (1994) Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 344:82-86
72. Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science 277:55-60
73. Mancuso P, Burlini A, Pruneri G et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661
74. Millauer B, Wizigmann-Voos S, Schnurch H et al (1993) High affinity vegf binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72:835-846
75. Moriyama T, Kataoka H, Koono M et al (1999) Expression of hepatocyte growth factor/scatter factor and its receptor c-met in brain tumors: evidence for a role in progression of astrocytic tumors (review). Int J Mol Med 3:531-536
76. Newton HB (2003) Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors, part 1: growth factor and ras signaling pathways. Expert Rev Anticancer Ther 3:595-614
77. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787
78. Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892-6899
79. Omuro AM, Faivre S, Raymond E (2007) Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 6:1909-1919
80. Papapetropoulos A, Garcia-Cardena G, Madri JA et al (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100:3131-3139
81. Pennacchietti S, Michieli P, Galluzzo M et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361
82. Plate KH, Breier G, Weich HA et al (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848
83. Plate KH, Breier G, Weich HA et al (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of vegf receptors, distribution of vegf protein and possible in vivo regulatory mechanisms. Int J Cancer 59:520-529
84. Pope WB, Lai A, Nghiemphu P et al (2006) Mri in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260
85. Rajantie I, Ilmonen M, Alminaite A et al (2004) Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104:2084-2086
86. Raymond E, Brandes A, Van Oosterom A et al (2004) Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an eortc: Nddg/btg intergroup study. J Clin Oncol (meeting abstracts) 22:1501
87. Reardon D, Friedman H, Yung WKA et al (2004) A phase I/II trial of ptk787/zk 222584 (ptk/zk), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (gbm). J Clin Oncol (meeting abstracts) 22:1513
88. Reardon DA, Egorin MJ, Quinn JA et al (2005) Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 23:9359-9368
89. Reardon D, Fink K, Nabors B et al (2007) Phase IIa trial of cilengitide (emd121974) single-agent therapy in patients (pts) with recurrent glioblastoma (gbm): Emd 121974-009. J Clin Oncol (meeting abstracts) 25:2002
90. Reardon DA, Desjardins A, Vredenburgh JJ et al (2008) Safety and pharmacokinetics of doseintensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol 10:330-340
91. Reynolds TY, Rockwell S, Glazer PM (1996) Genetic instability induced by the tumor microenvironment. Cancer Res 56:5754-5757
92. Rich JN, Sathornsumetee S, Keir ST et al (2005) Zd6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res 11:8145-8157
93. Rubenstein JL, Kim J, Ozawa T et al (2000) Anti-vegf antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314
94. Ryan AJ, Wedge SR (2005) Zd6474-a novel inhibitor of vegfr and egfr tyrosine kinase activity. Br J Cancer 92(suppl 1):S6-S13
95. Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
96. Sandstrom M, Johansson M, Andersson U et al (2004) The tyrosine kinase inhibitor zd6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 91:1174-1180
97. Santarelli JG, Udani V, Yung CY et al (2005) Preuss resident research award: bone marrowderived flk-1-expressing cd34+ cells contribute to the endothelium of tumor vessels in mouse brain. Clin Neurosurg 52:384-388
98. Sathornsumetee S, Cao Y, Marcello JE et al (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271-278
99. Schmidt NO, Westphal M, Hagel C et al (1999) Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10-18
100. Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985
101. Shweiki D, Itin A, Soffer D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845
102. Stark-Vance V (2005) Bevacizumab and cpt-11 in the treatment of relapsed malignant glioma. Neuro Oncol (meeting abstracts) 7:369
103. Stratmann A, Risau W, Plate KH (1998) Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459-1466
104. Stupp R, Goldbrunner R, Neyns B et al (2007) Phase I/IIa trial of cilengitide (emd121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (gbm). J Clin Oncol (meeting abstracts) 25:2000
105. Suddith RL, Kelly PJ, Hutchison HT et al (1975) In vitro demonstration of an endothelial proliferative factor produced by neural cell lines. Science 190:682-684
106. Takahashi JA, Mori H, Fukumoto M et al (1990) Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mrna and peptide in tumor tissues. Proc Natl Acad Sci USA 87:5710-5714
107. Takano S, Gately S, Engelhard H et al (1994) Suramin inhibits glioma cell proliferation in vitro and in the brain. J Neurooncol 21:189-201
108. Tong RT, Boucher Y, Kozin SV et al (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736
109. Tsai JC, Goldman CK, Gillespie GY (1995) Vascular endothelial growth factor in human glioma cell lines: induced secretion by egf, pdgf-bb, and bfgf. J Neurosurg 82:864-873
110. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al (2007a) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729
111. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007b) Phase II trial of bevacizumab and ironotecan in recurrent malignant gliomas. Clin Cancer Res 13:1253-1259
112. Wachsberger PR, Burd R, Cardi C et al (2007) Vegf trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 67:1526-1537
113. Wang D, Anderson JC, Gladson CL (2005) The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol 15:318-326
114. Weinmann M, Belka C, Plasswilm L (2004) Tumour hypoxia: impact on biology, prognosis and treatment of solid malignant tumours. Onkologie 27:83-90
115. Wen P Y, Yung WKA, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North american brain tumor consortium study 99-08. Clin Cancer Res 12:4899-4907
116. Willett CG, Boucher Y, Di Tomaso E et al (2004) Direct evidence that the vegf-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147
117. Wood JM, Bold G, Buchdunger E et al (2000) Ptk787/zk 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178-2189
118. Yu C, Friday BB, Lai JP et al (2006) Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through akt and c-jun nh2-terminal kinase pathways. Mol Cancer Ther 5:2378-2387
119. Yuan F, Chen Y, Dellian M et al (1996) Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765-14770
120. Zadeh G, Qian B, Okhowat A et al (2004) Targeting the tie2/tek receptor in astrocytomas. Am J Pathol 164:467-476
121. Zagzag D, Miller DC, Sato Y et al (1990) Immunohistochemical localization of basic fibroblast growth factor in astrocytomas. Cancer Res 50:7393-7398
122. Zagzag D, Hooper A, Friedlander DR et al (1999) In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 159:391-400
123. Zagzag D, Amirnovin R, Greco MA et al (2000a) Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 80:837-849
124. Zagzag D, Friedlander DR, Margolis B et al (2000b) Molecular events implicated in brain tumor angiogenesis and invasion. Pediatr Neurosurg 33:49-55
125. Zagzag D, Zhong H, Scalzitti JM et al (2000c) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618
126. Zeng H, Dvorak HF, Mukhopadhyay D (2001) Vascular permeability factor (vpf)/vascular endothelial growth factor (vegf) peceptor-1 down-modulates vpf/vegf receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinasedependent pathways. J Biol Chem 276:26969-26979
127. Zhang H, Vakil V, Braunstein M et al (2005) Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 105:3286-3294